Free Trial

BioCardia Q2 2023 Earnings Report

BioCardia logo
$2.26 +0.08 (+3.67%)
(As of 05:34 PM ET)

BioCardia EPS Results

Actual EPS
-$2.55
Consensus EPS
-$2.25
Beat/Miss
Missed by -$0.30
One Year Ago EPS
N/A

BioCardia Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.34 million
Beat/Miss
Missed by -$300.00 thousand
YoY Revenue Growth
N/A

BioCardia Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

We recommended Palantir in 2021, now we’re recommending this... (Ad)

My research indicates there is only one investment that can meet AI's unprecedented demand for energy.

Click to get the name and ticker symbol

BioCardia Earnings Headlines

We recommended Palantir in 2021, now we’re recommending this...
My research indicates there is only one investment that can meet AI's unprecedented demand for energy.
BioCardia Reports Q3 2024 Progress and Financials
BioCardia’s Strong Q3 Performance and Strategic Trials Drive Buy Rating
See More BioCardia Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioCardia? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioCardia and other key companies, straight to your email.

About BioCardia

BioCardia (NASDAQ:BCDA), a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

View BioCardia Profile

More Earnings Resources from MarketBeat